Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug Administration
Arthritis & Rheumatism2002Vol. 46(12), pp. 3151–3158
Citations Over TimeTop 1% of 2002 papers
Abstract
Although data from a case series such as this cannot establish a clear causal relationship between exposure to these medications and the risk of lymphoproliferative disease, the known predisposition of patients with RA and CD to lymphoma, the known excess of lymphoma in other immunosuppressed populations, and the known immunosuppressive effects of the anti-TNF drugs provide a biologic basis for concern and justification for the initiation of additional epidemiologic studies to formally evaluate this possible association.
Related Papers
- → Circulating complexes between tumour necrosis factor‐alpha and etanercept predict long‐term efficacy of etanercept in juvenile idiopathic arthritis(2015)28 cited
- Etanercept therapy-associated acute uveitis: a case report and literature review.(2010)
- → Tumour necrosis factor-α/etanercept complexes in serum predict long-term efficacy of etanercept treatment in seronegative rheumatoid arthritis(2017)12 cited
- A preliminary study of etanercept in the treatment of severe, resistant psoriatic arthritis.(2001)
- → Etanercept(2005)4 cited